Altimmune released mid-stage data Tuesday showing pemvidutide helped reduce patients’ weight by 10%, but the company’s shares tumbled 55% over safety concerns with the obesity drug.
Tag Archive for: NASH
CytoDyn has spent the past two years under siege – from the FDA, disgruntled investors and by association, the U.S. Department of Justice. Now, the company’s leadership hopes to chart a new future in non-alcoholic fatty liver disease.
2022 featured pivotal data that could change the landscape in non-alcoholic steatohepatitis, Alzheimer’s disease, sickle cell disease and many more indications.
The positive data sets the stage for the drug, resmetirom, to become the first approved treatment for NASH, or nonalcoholic steatohepatitis, a disease that affects about 5% of adults in the United States.
As a result of the industry’s steady progress in the clinic, coupled with the enormous commercial opportunity inherent in NASH, NASH stocks soared over the course of 2014 to 2018. Then, the bottom fell out.
Supply problems with the weight loss drug Wegovy were a stumbling block to growth, but Novo Nordisk has rallied.
For many in the biotech space, the pandemic was a chance to prove their worth, creating vaccines in record time and, for some, earning significant profits. Now, with the pandemic receding amidst rumblings of a global recession, the industry is facing what some consider the worst times since its inception.